ArticleCell genomics2022
Genome-wide risk prediction of common diseases across ancestries in one million people.
Article in Cell genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effect of scutellaria baicalensis and its active ingredients on major depressive disorder: a systematic review and meta-analysis of literature in pre-clinical research.Frontiers in pharmacology · 2024Pooled it
- Inherited risk of coronary artery disease: redefining care with imaging and genetics.Nature reviews. Cardiology · 2026Review
- Review
- Association and risk prediction of 19 complex diseases with polygenic scores and socioeconomic status.Communications medicine · 2026Article
- Multiple instance fine-mapping: Predicting causal regulatory variants with a deep sequence model.PLoS genetics · 2026Article
- Long-term impact of stressful life events on breast cancer risk: A 36-year genetically informed prospective study in the Finnish Twin Cohort.International journal of cancer · 2026Article
- Ancestry-specific performance of variant effect predictors in clinical variant classification.bioRxiv : the preprint server for biology · 2026Article
- Preventing premature deaths through polygenic risk scores.Nature communications · 2026Article
- Concordance of genetic determinants of acute coronary artery disease between European and Chinese populations.GigaScience · 2026Article
- Population-specific optimization of polygenic risk scores for breast cancer in East Asians.Genetics in medicine open · 2026Article
- Recommendations for responsible use of population descriptors in polygenic risk score development.Nature genetics · 2025Review
- Analysis of left ventricular mass for African American individuals using multi-ancestry polygenic risk scores: the Jackson Heart Study.Open heart · 2025Article
- Genetics of Cholesterol and Coronary Disease Risk across Six Global Ancestries.NEJM evidence · 2025Article
- Investigating the role of neighborhood socioeconomic status and germline genetics on prostate cancer risk.HGG advances · 2025Article
- The impact of polygenic score and socioeconomic status in predicting risk for 19 complex diseases.medRxiv : the preprint server for health sciences · 2025Article
- The Role of Polygenic Risk Score in the General Population: Current Status and Future Prospects.Journal of atherosclerosis and thrombosis · 2025Review
- Cross-biobank generalizability and accuracy of electronic health record-based predictors compared to polygenic scores.Nature genetics · 2025Article
- Bottlenecks in advancing and applying multiomic data integration-common data resources as rate-limiting drivers-the high-impact use case of atherosclerotic cardiovascular disease.Briefings in bioinformatics · 2025Review
- Clinical use of polygenic scores in type 2 diabetes: challenges and possibilities.Diabetologia · 2025Review
- Investigating the sources of variable impact of pathogenic variants in monogenic metabolic conditions.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Polygenic risk scores (PRS) measure genetic disease susceptibility by combining risk effects across the genome. For coronary artery disease (CAD), type 2 diabetes (T2D), and breast and prostate cancer, we performed cross-ancestry evaluation of genome-wide PRSs in six biobanks in Europe, the United States, and Asia. We studied transferability of these highly polygenic, genome-wide PRSs across global ancestries, within European populations with different health-care systems, and local population substructures in a population isolate. All four PRSs had similar accuracy across European and Asian populations, with poorer transferability in the smaller group of individuals of African ancestry. The PRSs had highly similar effect sizes in different populations of European ancestry, and in early- and late-settlement regions with different recent population bottlenecks in Finland. Comparing genome-wide PRSs to PRSs containing a smaller number of variants, the highly polygenic, genome-wide PRSs generally displayed higher effect sizes and better transferability across global ancestries. Our findings indicate that in the populations investigated, the current genome-wide polygenic scores for common diseases have potential for clinical utility within different health-care settings for individuals of European ancestry, but that the utility in individuals of African ancestry is currently much lower.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.